SCHEMBL1703074

SCHEMBL1703074

Cc1cc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)ccc1F

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.78
FLT3 P36888 15/20 0.78
CSF1R P07333 13/20 0.78
KIT P10721 13/20 0.78
FLT4 P35916 13/20 0.78
FLT1 P17948 12/20 0.78
BLK P51451 12/20 0.78
LYN P07948 11/20 0.78
LCK P06239 11/20 0.78
DYRK3 O43781 5/20 0.78
ROCK2 O75116 5/20 0.78
MAP4K4 O95819 5/20 0.78
RET P07949 5/20 0.78
FGFR1 P11362 5/20 0.78
RPS6KB1 P23443 5/20 0.78
FRK P42685 5/20 0.78
CLK2 P49760 5/20 0.78
RPS6KA3 P51812 5/20 0.78
MAP4K2 Q12851 5/20 0.78
ROCK1 Q13464 5/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702841 0.89 KDR (0.78) KDRFLT3CSF1RKITFLT4
SCHEMBL1702967 0.88 KDR (1.00) KDRFLT3CSF1RKITFLT4
SCHEMBL1702951 0.86 KDR (0.80) KDRFLT3CSF1RKITFLT4
SCHEMBL1702898 0.85 KDR (1.00) KDRFLT3CSF1RKITFLT4
SCHEMBL1702879 0.84 KDR (1.00) KDRFLT3CSF1RKITFLT4
SCHEMBL1702965 0.83 KDR (0.79) KDRFLT3CSF1RKITFLT4
SCHEMBL1703600 0.83 KDR (0.78) KDRFLT3CSF1RKITFLT4
SCHEMBL1703583 0.82 KIT (1.00) KDRFLT3CSF1RKITFLT4
SCHEMBL1703245 0.80 KDR (0.78) KDRFLT3CSF1RKITFLT4
SCHEMBL1703142 0.79 KDR (1.00) KDRFLT3CSF1RKITFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885FLT3 79/4885CSF1R 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.